-
Autor
Bamias, Aristotelis 1 Carles, Joan 1 Castellano, Daniel 1 Eymard, Jean-Christophe 1 Feyerabend, Susan 1 Fizazi, Karim 1 Geffriaud-Ricouard, Christine 1 Helissey, Carole 1 Iacovelli, Roberto 1 Kramer, Gero 1 Melichar, Bohuslav 1 Ozatilgan, Ayse 1 Sternberg, Cora N 1 Sverrisdóttir, Ásgerður 1 Theodore, Christine 1 Tombal, Bertrand 1 Wülfing, Christian 1 de Bono, Johann 1 de Wit, Ronald 1
- Organizace
-
Pracoviště
12 de Octubre University Hospital Madrid 1 Alexandra Hospital National and Kapod... 1 Azienda Ospedaliera Universitaria Int... 1 Englander Institute for Precision Med... 1 From the Erasmus Medical Center Rotte... 1 Institut Gustave Roussy and Universit... 1 Institut de Recherche Clinique Univer... 1 Landspitali University Hospital Reykj... 1 Palacky University Medical School and... 1 Sanofi Global Medical Oncology Cambri... 1 Vall d'Hebron Institute of Oncology V... 1 the Department of Urology Asklepios T... 1 the Institute of Cancer Research and ... 1 the Medical University of Vienna Vienna 1
- Formát
- Publikační typ
- Check Tag
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
-
Autor
Bamias, Aristotelis 1 Carles, Joan 1 Castellano, Daniel 1 Eymard, Jean-Christophe 1 Feyerabend, Susan 1 Fizazi, Karim 1 Geffriaud-Ricouard, Christine 1 Helissey, Carole 1 Iacovelli, Roberto 1 Kramer, Gero 1 Melichar, Bohuslav 1 Ozatilgan, Ayse 1 Sternberg, Cora N 1 Sverrisdóttir, Ásgerður 1 Theodore, Christine 1 Tombal, Bertrand 1 Wülfing, Christian 1 de Bono, Johann 1 de Wit, Ronald 1
- Organizace
-
Pracoviště
12 de Octubre University Hospital Madrid 1 Alexandra Hospital National and Kapod... 1 Azienda Ospedaliera Universitaria Int... 1 Englander Institute for Precision Med... 1 From the Erasmus Medical Center Rotte... 1 Institut Gustave Roussy and Universit... 1 Institut de Recherche Clinique Univer... 1 Landspitali University Hospital Reykj... 1 Palacky University Medical School and... 1 Sanofi Global Medical Oncology Cambri... 1 Vall d'Hebron Institute of Oncology V... 1 the Department of Urology Asklepios T... 1 the Institute of Cancer Research and ... 1 the Medical University of Vienna Vienna 1
- Formát
- Publikační typ
- Check Tag
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
-
de Wit, Ronald
Autor de Wit, Ronald From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.) the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.) Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.) Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne-Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d'Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) - all in France Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.) the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) - both in Germany the Medical University of Vienna, Vienna (G.K.) Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.) Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona (J.C.) Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome - both in Italy (R.I.) Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.) Landspitali University Hospital, Reykjavik, Iceland (Á.S.) Sanofi, Global Medical Oncology, Cambridge, MA (A.O.) and 12 de Octubre University Hospital, Madrid (D.C.)
-
de Bono, Johann
Autor de Bono, Johann From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.) the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.) Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.) Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne-Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d'Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) - all in France Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.) the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) - both in Germany the Medical University of Vienna, Vienna (G.K.) Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.) Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona (J.C.) Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome - both in Italy (R.I.) Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.) Landspitali University Hospital, Reykjavik, Iceland (Á.S.) Sanofi, Global Medical Oncology, Cambridge, MA (A.O.) and 12 de Octubre University Hospital, Madrid (D.C.)
-
Sternberg, Cora N
Autor Sternberg, Cora N From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.) the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.) Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.) Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne-Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d'Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) - all in France Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.) the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) - both in Germany the Medical University of Vienna, Vienna (G.K.) Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.) Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona (J.C.) Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome - both in Italy (R.I.) Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.) Landspitali University Hospital, Reykjavik, Iceland (Á.S.) Sanofi, Global Medical Oncology, Cambridge, MA (A.O.) and 12 de Octubre University Hospital, Madrid (D.C.)
-
Fizazi, Karim
Autor Fizazi, Karim From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.) the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.) Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.) Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne-Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d'Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) - all in France Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.) the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) - both in Germany the Medical University of Vienna, Vienna (G.K.) Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.) Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona (J.C.) Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome - both in Italy (R.I.) Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.) Landspitali University Hospital, Reykjavik, Iceland (Á.S.) Sanofi, Global Medical Oncology, Cambridge, MA (A.O.) and 12 de Octubre University Hospital, Madrid (D.C.)
-
Tombal, Bertrand
Autor Tombal, Bertrand From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.) the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.) Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.) Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne-Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d'Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) - all in France Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.) the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) - both in Germany the Medical University of Vienna, Vienna (G.K.) Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.) Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona (J.C.) Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome - both in Italy (R.I.) Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.) Landspitali University Hospital, Reykjavik, Iceland (Á.S.) Sanofi, Global Medical Oncology, Cambridge, MA (A.O.) and 12 de Octubre University Hospital, Madrid (D.C.)
-
Wülfing, Christian
Autor Wülfing, Christian From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.) the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.) Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.) Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne-Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d'Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) - all in France Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.) the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) - both in Germany the Medical University of Vienna, Vienna (G.K.) Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.) Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona (J.C.) Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome - both in Italy (R.I.) Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.) Landspitali University Hospital, Reykjavik, Iceland (Á.S.) Sanofi, Global Medical Oncology, Cambridge, MA (A.O.) and 12 de Octubre University Hospital, Madrid (D.C.)
-
Kramer, Gero
Autor Kramer, Gero From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.) the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.) Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.) Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne-Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d'Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) - all in France Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.) the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) - both in Germany the Medical University of Vienna, Vienna (G.K.) Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.) Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona (J.C.) Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome - both in Italy (R.I.) Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.) Landspitali University Hospital, Reykjavik, Iceland (Á.S.) Sanofi, Global Medical Oncology, Cambridge, MA (A.O.) and 12 de Octubre University Hospital, Madrid (D.C.)
-
Eymard, Jean-Christophe
Autor Eymard, Jean-Christophe From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.) the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.) Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.) Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne-Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d'Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) - all in France Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.) the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) - both in Germany the Medical University of Vienna, Vienna (G.K.) Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.) Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona (J.C.) Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome - both in Italy (R.I.) Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.) Landspitali University Hospital, Reykjavik, Iceland (Á.S.) Sanofi, Global Medical Oncology, Cambridge, MA (A.O.) and 12 de Octubre University Hospital, Madrid (D.C.)
-
Bamias, Aristotelis
Autor Bamias, Aristotelis From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.) the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.) Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.) Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne-Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d'Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) - all in France Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.) the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) - both in Germany the Medical University of Vienna, Vienna (G.K.) Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.) Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona (J.C.) Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome - both in Italy (R.I.) Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.) Landspitali University Hospital, Reykjavik, Iceland (Á.S.) Sanofi, Global Medical Oncology, Cambridge, MA (A.O.) and 12 de Octubre University Hospital, Madrid (D.C.)
-
Carles, Joan
Autor Carles, Joan From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.) the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.) Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.) Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne-Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d'Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) - all in France Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.) the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) - both in Germany the Medical University of Vienna, Vienna (G.K.) Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.) Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona (J.C.) Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome - both in Italy (R.I.) Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.) Landspitali University Hospital, Reykjavik, Iceland (Á.S.) Sanofi, Global Medical Oncology, Cambridge, MA (A.O.) and 12 de Octubre University Hospital, Madrid (D.C.)
Nursing & Allied Health Database (ProQuest) od 1980-01-03 do Před 3 měsíci
Health & Medicine (ProQuest) od 1980-01-03 do Před 3 měsíci
Family Health Database (ProQuest) od 1980-01-03 do Před 3 měsíci
Psychology Database (ProQuest) od 1980-01-03 do Před 3 měsíci
Health Management Database (ProQuest) od 1980-01-03 do Před 3 měsíci
Public Health Database (ProQuest) od 1980-01-03 do Před 3 měsíci
PubMed
31566937
DOI
10.1056/nejmoa1911206
Knihovny.cz E-zdroje
BACKGROUND: The efficacy and safety of cabazitaxel, as compared with an androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and had progression within 12 months while receiving the alternative inhibitor (abiraterone or enzalutamide) are unclear. METHODS: We randomly assigned, in a 1:1 ratio, patients who had previously received docetaxel and an androgen-signaling-targeted inhibitor (abiraterone or enzalutamide) to receive cabazitaxel (at a dose of 25 mg per square meter of body-surface area intravenously every 3 weeks, plus prednisone daily and granulocyte colony-stimulating factor) or the other androgen-signaling-targeted inhibitor (either 1000 mg of abiraterone plus prednisone daily or 160 mg of enzalutamide daily). The primary end point was imaging-based progression-free survival. Secondary end points of survival, response, and safety were assessed. RESULTS: A total of 255 patients underwent randomization. After a median follow-up of 9.2 months, imaging-based progression or death was reported in 95 of 129 patients (73.6%) in the cabazitaxel group, as compared with 101 of 126 patients (80.2%) in the group that received an androgen-signaling-targeted inhibitor (hazard ratio, 0.54; 95% confidence interval [CI], 0.40 to 0.73; P<0.001). The median imaging-based progression-free survival was 8.0 months with cabazitaxel and 3.7 months with the androgen-signaling-targeted inhibitor. The median overall survival was 13.6 months with cabazitaxel and 11.0 months with the androgen-signaling-targeted inhibitor (hazard ratio for death, 0.64; 95% CI, 0.46 to 0.89; P = 0.008). The median progression-free survival was 4.4 months with cabazitaxel and 2.7 months with an androgen-signaling-targeted inhibitor (hazard ratio for progression or death, 0.52; 95% CI, 0.40 to 0.68; P<0.001), a prostate-specific antigen response occurred in 35.7% and 13.5% of the patients, respectively (P<0.001), and tumor response was noted in 36.5% and 11.5% (P = 0.004). Adverse events of grade 3 or higher occurred in 56.3% of patients receiving cabazitaxel and in 52.4% of those receiving an androgen-signaling-targeted inhibitor. No new safety signals were observed. CONCLUSIONS: Cabazitaxel significantly improved a number of clinical outcomes, as compared with the androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who had been previously treated with docetaxel and the alternative androgen-signaling-targeted agent (abiraterone or enzalutamide). (Funded by Sanofi; CARD ClinicalTrials.gov number, NCT02485691.).
- MeSH
- androsteny aplikace a dávkování škodlivé účinky MeSH
- antagonisté androgenů aplikace a dávkování škodlivé účinky MeSH
- doba přežití bez progrese choroby MeSH
- fenylthiohydantoin aplikace a dávkování škodlivé účinky analogy a deriváty MeSH
- intravenózní infuze MeSH
- Kaplanův-Meierův odhad MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory prostaty rezistentní na kastraci farmakoterapie mortalita MeSH
- prednison aplikace a dávkování MeSH
- protokoly antitumorózní kombinované chemoterapie škodlivé účinky terapeutické užití MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- taxoidy aplikace a dávkování škodlivé účinky MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- srovnávací studie MeSH
Sdílet
Název dokumentu
Po ukončení testovacího provozu bude odkaz přesměrován adresu produkční verze portálu Medvik.